References
- Buttram VC, Jr., Reiter RC. 1981. Uterine leiomyomata: etiology, symptomatology, and management. Fertility and Sterility 36:433–445.
- Dlugi AM, Miller JD, Knittle J. 1990. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomised, placebo-controlled, double-blind study. Lupron Study Group. Fertility and Sterility 54:419–427.
- Han SC, Kim MD, Jung DC, et al. 2013. Degeneration of leiomyoma in patients referred for uterine fibroid embolization: incidence, imaging features and clinical characteristics. Yonsei Medical Journal 54:215–219.
- Hornstein MD, Surrey ES, Weisberg GW, et al. 1998. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron add-back study group. Obstetrics & Gynecology 91:16–24.
- Kawakami S, Togashi K, Konishi I, et al. 1994. Red degeneration of uterine leiomyoma: MR appearance. Journal of Computer Assisted Tomography 18:925–928.
- Khan AT, Shehmar M, Gupta JK. 2014. Uterine fibroids: current perspectives. International Journal of Women's Health 6:95–114.
- Lethaby A, Vollenhoven B, Sowter M. 2002. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. British Journal of Obstetrics and Gynaecology 109:1097–1108.
- Magon N. 2011. Gonadotropin releasing hormone agonists: Expanding vistas. Indian Journal of and Metabolism 15:261–267.
- Matta WH, Shaw RW, Nye M. 1989. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. British Journal of Obstetrics and Gynaecology 96:200–206.
- Murase E, Siegelman ES, Outwater EK, Perez-Jaffe LA, Tureck RW. 1999. Uterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatment. Radiographics 19:1179–1197.